What Infuse Life Sciences does

Infuse Life Sciences (legal entity: infuse Life Science, Inc. / インフューズライフサイエンス株式会社) is a Tokyo-based, privately held medical device and life sciences consulting company founded in October 2024 and incorporated in December 2024, headquartered at Incubation Office TAMA in Akishima-shi, Tokyo. The company operates in women's health with a focus on obstetrics, gynecology, and reproductive medicine, building a portfolio of proprietary pre-commercial diagnostic and therapeutic devices targeting the fallopian tube — a structurally underserved organ in reproductive medicine. Its lead device is a single-use disposable endoscopic system intended as a radiation-free, non-invasive alternative to hysterosalpingography (HSG), with patent applications pending; a second therapeutic catheter for simplified infertility treatment completed prototyping in March 2026, and a 2027 regulatory market launch is targeted.

The core technology stack combines a disposable endoscopic architecture (eliminating complex high-level sterilization) with radiation-free imaging and simplified catheter mechanics, protected by pending patents and supported by AMED, Tokyo Metropolitan Femtech, and Tokyo Medical Device Industry Entry grants. Beyond devices, the company operates a life sciences consulting practice that delivers Business Model Canvas workshops, clinical workflow analysis, and real-world clinical immersion to Japanese and international pharma, biotech, and medtech clients, with services starting at JPY 50,000 and structured as multi-year custom engagements.

The business model is dual-track: near-term professional services revenue from consulting (4 active clients across 6 projects, Q1 2025 sales at 122% of target, with very low burn and >200 months runway excluding grant-funded portion) layered against a longer-term medical device commercialization pipeline expected to monetize post-2027 PMDA approval. The company also sells branded merchandise via Suzuri.jp. Strategic positioning was materially upgraded in June 2026 through a partnership with Alira Health, which makes iLS Alira's Japan representative and provides embedded access to a global life sciences advisory network; a July 2026 funding round from BD Fund and Incubate Fund is explicitly directed at flagship device R&D and US market entry preparation. The 11-person team is led by CEO Dai Saito (ex-Konica Minolta ob-gyn R&D with US FDA submission experience) and CMO Dr. Yukio Suzuki (Columbia University postdoc, ~60 English-language publications), supported by senior advisors with 50+ years of medical device R&D experience.

Name

Infuse Life Sciences

Legal name

infuse Life Science, Inc. / インフューズライフサイエンス株式会社

Website

https://infuselifescience.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Infuse Life Sciences is a Tokyo-based medical device and consulting firm developing proprietary disposable endoscopic and catheter products for infertility diagnosis in obstetrics and gynecology, while providing life sciences business model consulting to Japanese and international pharma, biotech, and medtech clients.

Ownership category

akta.pro rank

Product category

Women's Health Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Other Scientific and Technical Consulting Services (54169)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs) (HLAHANAG)

akta.pro secondary industry

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

Keywords

• Women's health devices
• Gynecology medical devices
• Fertility diagnostics
• Reproductive medicine consulting
• Fallopian tube endoscopy

Headquarters

HQ city

Akishima

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Life Sciences Consulting Services: Consulting services to sharpen and realize ideas for healthcare products and services. Includes Business Model Canvas workshops, clinical workflow analysis, and real-world clinical immersion. Services provided in both Japanese and English. The company works hands-on with R&D and business teams to turn early-stage clinical insight into viable products and business strategies. Multiple projects running simultaneously with diverse clients including those from drug discovery field and international clients.
2. Medical Device Development: Development of proprietary medical devices for obstetrics and gynecology, including diagnostic and therapeutic devices for infertility treatment. Currently in prototype/development stage with regulatory approval targeted for 2027 market launch. Revenue expected upon commercialization.
3. Brand Merchandise: Sale of original brand merchandise including branded gears and products through the company's Suzuri online store.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Infuse Life Sciences develops proprietary disposable medical devices for obstetrics and gynecology, including a world-first fallopian tube endoscopic diagnostic system and a simplified infertility treatment catheter, both targeting 2027 market launch pending regulatory approval. The company concurrently operates a life sciences consulting practice that delivers Business Model Canvas workshops, clinical workflow analysis, and real-world clinical immersion to Japanese and international pharma, biotech, and medtech clients.

Product overview

Infuse Life Sciences is a medical device startup that develops a multi-product portfolio focused on obstetrics and gynecology. The core offerings consist of two medical devices under development: a disposable fallopian tube endoscopic diagnostic system and a simplified infertility treatment catheter. Both devices address the fallopian tube, a critical yet underserved organ in reproductive medicine. The company also operates a life sciences consulting division providing business model consulting services to healthcare companies. All medical devices are in development phase and have not received regulatory approval.

Differentiator

Problem solved

Functional benefit

Brands

• infuse Life Science Original Brand Gears: Original branded merchandise including products celebrating the beauty of life

Products and services

• Disposable Fallopian Tube Endoscopic System A single-use disposable endoscopic system for direct visualization of the fallopian tube, intended as a radiation-free, non-invasive alternative to hysterosalpingography (HSG) for diagnosing female infertility and gynecologic conditions. Designed for clinics without requiring complex sterilization processes.
• Simplified Infertility Treatment Catheter A therapeutic medical device for infertility treatment designed with simplified mechanisms compared to existing therapeutic devices, aiming to improve clinician usability and enable outpatient procedures.
• LS Consulting Services

Quantifiable outcome

• Prototype completed for diagnostic device targeting early detection of infertility causes
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Alira HealthcoreStrategic or Co-development Partner · 18 June 2026Regional partnership combining infuse Life Science's Japan-rooted medical device and IVD expertise with Alira Health's global life sciences strategy centered on pharmaceuticals and biotech. Partnership provides end-to-end consulting from strategy through execution, covering regulatory, clinical, market access, and commercialization. Alira Health has 600+ experts trusted by 75% of top 50 pharma/biotech and 80% of top 50 medtech companies. iLS serves as Alira Health's Japan representative.
• GREAT NetworksupportingGTM or Marketing Partner · 1 January 2026First-time sponsor participation in GREAT network meeting 2025. Increased awareness and recognition among key opinion leaders in emergency and intensive care medicine in Europe and the United States.
• Medical Device Manufacturer PartnerssupportingStrategic or Co-development Partner · 1 April 2025Partnership discussions initiated with several key investors and medical device manufacturers based on successful prototype completion. Collaboration discussions progressing smoothly with overwhelmingly positive feedback.
• Leading Cardiovascular KOL (Japan)supportingStrategic or Co-development Partner · 1 January 2025Partnership with leading key opinion leader in Japan for basic research starting point for developing world-first cardiovascular medical device. High expectations for this idea and technology to become significant business in future.
• NJ/USA-based Medical Device ConsultantsupportingImplementation/ SI/ Consulting PartnerPlanning to partner with consultant in New Jersey, USA who is active, knowledgeable, and experienced expert of medical device business development and strategy building.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Femasys: US-based clinical-stage medical device company focused on women's health, including novel solutions for infertility diagnosis and treatment. Most directly comparable as a women's-health medtech targeting the same underserved infertility workflows iLS addresses.
• Prescient Healthcare Group: Life sciences consulting firm offering business model strategy, clinical workflow analysis, and commercialization support to pharma and medtech clients. Directly comparable to iLS's consulting services arm.

Broad incumbents

• Karl Storz: Major endoscopic instrument manufacturer with deep presence in gynecology. Represents the type of incumbent whose reusable endoscope systems iLS's disposable design aims to disrupt.
• Hologic: Women's health-focused medical device company with diagnostic and surgical portfolios including fertility-related products. Provides comparable end-to-end women's health medtech positioning.
• Olympus: Global leader in endoscopic systems. iLS CEO spent 8+ years at an endoscope manufacturer and the disposable fallopian tube endoscope directly competes with traditional rigid and flexible endoscopes used in gynecology.
• Boston Scientific: Large diversified medtech with women's health and endoscopy franchises. Represents a likely incumbent response if disposable fallopian tube endoscopy achieves clinical traction.
• CooperSurgical: Specializes in medical devices for women's health including fertility, IVF, and reproductive medicine. Direct overlap in clinical workflows and patient segments iLS targets.
• Cook Medical: Global medical device manufacturer with strong catheter and infertility product lines. The simplified infertility treatment catheter competes directly with established Cook Medical catheter offerings.

Emerging players

• CrossBay Medical: Emerging women's health medical device company developing single-use intrauterine tools. Comparable as a niche innovator serving OB-GYN procedural workflows.
• Inscope Medical: Emerging player developing single-use, disposable endoscopic technologies. Shares iLS's disposable-endoscope thesis and is the type of emerging competitor that could compete for the same clinical niche.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Infuse Life Sciences